117- Williams JM, Murphy S, Burke M, Roman RJ. 20-hydroxyeicosatetraeonic acid: a new target
for the treatment of hypertension. J Cardiovasc Pharmacol. 2010;56(4):336–44. - Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function.
Physiol Rev. 2002;82(1):131–85. - Wainford RD, Carmichael CY, Pascale CL, Kuwabara JT. Galphai2-protein-mediated signal
transduction: central nervous system molecular mechanism countering the development of
sodium-dependent hypertension. Hypertension. 2015;65(1):178–86. - Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S, et al. Involvement of
bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015;117(2):178–91. - Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, et al. Brain microglial cytokines in
neurogenic hypertension. Hypertension. 2010;56(2):297–303. - Lazartigues E. Is microglia the new target for the treatment of resistant hypertension?
Hypertension. 2015;66(2):265–6. - Shen XZ, Li Y, Li L, Shah KH, Bernstein KE, Lyden P, et al. Microglia participate in neuro-
genic regulation of hypertension. Hypertension. 2015;66(2):309–16. - Desir GV. Regulation of blood pressure and cardiovascular function by renalase. Kidney Int.
2009;76(4):366–70. - Desir GV. Role of renalase in the regulation of blood pressure and the renal dopamine system.
Curr Opin Nephrol Hypertens. 2011;20(1):31–6. - Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, et al. Evidence for a link between
gut microbiota and hypertension in the Dahl rat. Physiol Genomics. 2015;47(6):187–97. - Davern PJ, Chowdhury S, Jackson KL, Nguyen-Huu TP, Head GA. GABAA receptor dys-
function contributes to high blood pressure and exaggerated response to stress in Schlager
genetically hypertensive mice. J Hypertens. 2014;32(2):352–62. - Brown NJ. This is not Dr. Conn’s aldosterone anymore. Trans Am Clin Climatol Assoc.
2011;122:229–43. - Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated
with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs
Ther Sponsored Int Soc Cardiovasc Pharmacother. 1995;9(1):145–9. - Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage.
Curr Hypertens Rep. 2000;2(3):327–34. - Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor
therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res.
2001;29(1):13–21. - Shamkhlova M, Trubitsyna NP, Katsaia GV, Goncharov NP, Malysheva NM, Il’in AV, et al.
The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and dia-
betic nephropathy. Ter Arkh. 2008;80(1):49–52. - Jansen PM, Hofland J, van den Meiracker AH, de Jong FH, Danser AH. Renin and prorenin
have no direct effect on aldosterone synthesis in the human adrenocortical cell lines H295R
and HAC15. J Renin Angiotensin Aldosterone Syst JRAAS. 2012;13(3):360–6. - Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reac-
tivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system block-
ade: is oral renin inhibition the solution? Expert Opin Pharmacother. 2007;8(5):529–35. - Cherney DZ, Lai V, Miller JA, Scholey JW, Reich HN. The angiotensin II receptor type 2
polymorphism influences haemodynamic function and circulating RAS mediators in nor-
motensive humans. Nephrol Dial, Transplant Off Publ Eur Dial Transplant Assoc Eur Renal
Assoc. 2010;25(12):4093–6. - Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, et al. Failure of aldo-
sterone suppression despite angiotensin-converting enzyme (ACE) inhibitor adminis-
tration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol.
2001;37(7):1808–12. - Otani H, Otsuka F, Inagaki K, Suzuki J, Makino H. Roles of bone morphogenetic protein-6 in
aldosterone regulation by adrenocortical cells. Acta Med Okayama. 2010;64(4):213–8.
7 Pathophysiological Insights in Resistant Hypertension